News

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
Hims & Hers Health (NYSE:HIMS) on Wednesday announced plans to expand in Canada next year with the loss of market exclusivity for semaglutide, the popular weight loss drug marketed as Wegovy by Novo ...
Andrew Dudum, the co-founder and CEO of telehealth company Hims & Hers, on Monday sought to clarify a recent post on X (formerly Twitter) regarding on-campus protests against the war in Gaza.
Andrew Dudum has played a role in 12 plus companies, raised hundreds of millions of dollars in the process, and have created a venture producing machine. What is he up to now?
Kevin O'Leary sounded off on Hims & Hers CEO Andrew Dudum over his initial support of the anti-Israel protests and said he would have been fired in seconds if he worked for him.
Andrew Dudum joins a growing number of entrepreneurs who are going public via SPAC. (Courtesy of Hims) 2021-01-21T21:15:15Z ...
Kevin O'Leary, the host of "Shark Tank," criticized Andrew Dudum, the CEO of Hims & Hers, for his support of pro-Palestinian student protests. O'Leary suggested that Dudum should have been fired ...
Stock in Hims, a sexual health brand, fell 8 percent Friday after founder and CEO Andrew Dudum, left, praised pro-Palestine protesters and invited them to apply to his company.
Andrew Dudum is a disrupter. In 2017 he founded Hims & Hers (NYSE: HIMS), a digital health startup with the goal of upending the traditional healthcare market.
Andrew Dudum is a well-known figure in the entrepreneurial and healthcare sectors, having co-founded Hims & Hers Health Inc, a company that has been at the forefront of the telehealth revolution.